Novartis Archives -

Market Access/ News/ News/ News/ Patients

GSK pledges £1bn drive for infectious disease R&D

Phil Taylor developing countries, GlaxoSmithKline, HIV, infectious diseases, Malaria, Novartis, patients, tropical diseases, tuberculosis 0 Comment

GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious

GSK pledges £1bn drive for infectious disease R&D

https://pharmaphorum.com/news/gsk-pledges-1bn-drive-for-infectious-disease-rd/

News/ News/ News/ Oncology/ Sales and Marketing

Novartis bags FDA okay for BRAF-positive tumour combination

Phil Taylor BRAF, Mekinist, Novartis, novel targeted cancer treatments, Oncology, Tabrecta, Tafinlar 0 Comment

Novartis’ two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for

Novartis bags FDA okay for BRAF-positive tumour combination

https://pharmaphorum.com/news/novartis-bags-fda-okay-for-braf-positive-tumour-combination/

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

News/ News/ R&D

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Phil Taylor beta thalassaemia, gene editing, Haematology, Novartis, partnering, Precision BioSciences, sickle cell disease 0 Comment

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

https://pharmaphorum.com/news/precision-bio-climbs-on-near-1-5bn-sickle-cell-pact-with-novartis/

News/ News/ Sales and Marketing

Novartis faces threat of early generic of MS drug Gilenya in US

Phil Taylor generics, multiple sclerosis, Novartis, patent litigation 0 Comment

Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after

Novartis faces threat of early generic of MS drug Gilenya in US

https://pharmaphorum.com/news/novartis-faces-threat-of-early-generic-of-ms-drug-gilenya-in-us/

News/ News/ News/ Oncology/ R&D

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

News/ News/ R&D

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

Phil Taylor Amgen, atherosclerosis, gene silencing, lipoprotein(a), Novartis, olpasiran, pelacarsen, Silence Therapeutics, siRNA, SLN360 0 Comment

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

https://pharmaphorum.com/news/amgen-eyes-swift-move-to-ph3-for-cardiovascular-drug-olpasiran/

Market Access/ News/ News/ News/ Sales and Marketing

Roche puts pressure on SMA rivals with new FDA approval

Phil Taylor Biogen, Evrysdi, Novartis, PTC Therapeutics, regulatory approval, Roche, SMA, Spinraza, Zolgensma 0 Comment

Roche and PTC Therapeutics’ Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger

Roche puts pressure on SMA rivals with new FDA approval

https://pharmaphorum.com/news/roche-puts-pressure-on-sma-rivals-with-new-fda-approval/

Patients/ Views & Analysis/ Views and analysis

A crisis of trust: How lack of sector confidence is threating patient centricity

Amanda Barrell Novartis, patient centricity, Scott Bradley, trust in pharma 0 Comment

People who trust pharma are more interested in using the industry’s services – making building confidence in the

A crisis of trust: How lack of sector confidence is threating patient centricity

https://pharmaphorum.com/patients/a-crisis-of-trust-how-lack-of-sector-confidence-is-threating-patient-centricity/

Deep Dive/ Market Access/ Views & Analysis/ Views and analysis

Deep Dive: Market Access

mike.hammerton@pharmaphorum.com Axon, Deep Dive, market access, Medscape, Novartis, Takeda 0 Comment

For life science companies around the world, enabling faster access to innovative drugs and therapies is a complicated

Deep Dive: Market Access

https://pharmaphorum.com/market-access-2/deep-dive-market-access-2022/

Trending

Novartis

Login